ARTHEx to raise € 1.5 million in a seed round supported by Invivo Ventures
Arthex Biotech, a Valencia, Spain-based startup developing antisense RNA treatments against genetic diseases, announced closing a €1.5 million ($1.7M) seed round.
The money was provided by Invivo Ventures and will be used to optimize its therapy with the intention of carrying out regulatory studies and carrying out the first clinical trials in humans in 2022.
In conjunction with the announcement, Lluís Pareras and Albert Ferrer will join the board of directors of the company.
ARTHEx Biotech S.L. , founded in 2019 as a spin off of the University of Valencia by Rubén Artero and Beatriz Llamusí, is focused on the development of the next generation of antisense RNA (ribonucleic acid) therapies for the treatment of myotonic dystrophy type 1 (DM1). It is a neuromuscular disease of genetic origin that, despite the efforts made to date, does not yet have a treatment for its cure.